2.2. Intervention
The study intervention consisted of 3 days of inhalation (2 inhalations at each visit) with an AMSA device (ATOMISORAn atomizer, with a capacity of 12 mL, is a hand-held device fitted with a binary nasal adapter. It produces from an aerosol fluid with a particle size of 2.2 µm, emitted at a flow rate of 0.20 mL per minute [For the first inhalation, the aerosol was obtained from a solution composed of: 2.5 mL of ambroxol solution for nebulization (7.5 mg/mL) mixed with 1 mL of 0.9% saline. The second inhalation’s aerosol consisted of a suspension of 2 mL budesonide (0.25 mg/mL) mixed with 1 mL of 0.9% saline. In total, patients received 1.5 mg of budesonide and 56.25 mg of ambroxol by nebulization during three days of treatment.